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ABSTRACT 
Al-Mohannadi, Anjud K, Masters of Science: June: 2019, Biomedical Science 
Title: Visualization of Factor VIII With Flow-Cytometry As A Tool For A Novel 
Gene Therapy Approach In Hemophilia 
Supervisors of Thesis: Ahmed, M, Malki.and from Sidra Medicine: Sara Deola. 
Haemophilia A is a genetic X-linked disorder, characterized by coagulation Factor 
VIII (FVIII) deficiency and leading to pathological bleedings. The disease occurs in a rate 
of 1 in 5000 males’ births. The treatment is the administration of plasma-derived or 
recombinant Factor VIII which is expensive and leads to the development of inhibitory 
antibodies in around 40% of patients affected by the severe form of the disease. The disease 
becomes for these patients life-threatening.  
New approaches to treat Haemophilia include Gene Therapy (GT). Cells corrected 
through genetic modifications are used to produce in Haemophilia A patients FVIII protein 
in a sustained manner, as long-term treatment for this disorder. The cells of choice should 
be persistent and equipped with the machinery for large protein assembly and secretion. So 
far, target cells for Haemophilia gene correction are mostly liver cells, although they are 
highly immunogenic and exposed to immune-mediated destruction after GT. 
Based on literature evidences, Bone Marrow Transplantation can correct 
Haemophilia A in mice, providing evidence that Hematopoietic Stem Cells (HSC) or their 
progeny are able to produce FVIII. We chose the approach of correcting HSC with 
lentiviral vectors carrying the FVIII gene cassette.  
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Whereas classically FVIII protein is visualized on adherent cells through 
immunohistochemistry staining, Flow-Cytometry (FC) literature publications are very 
scarce. 
FC analysis is an attractive method for analysing hematopoietic cells, and in 
general, a versatile method for protein visualization. However, large proteins as FVIII are 
difficult to be carefully analysed, and the method requires several steps of optimization. 
This joint project with Dr. Muhammad Elnaggar, (postdoctoral fellow) .aims to 
optimize a method to characterize large proteins as FVIII with a reliable FC staining 
protocol. To this aim we used cell lines to evaluate the expression and secretion pathways 
of FVIII, the intracellular requirements to fold and secrete large proteins, and the toxicities 
of protein accumulation, in case of GT mediated protein overexpression. To this aim, the 
FC experiments were performed to optimise the FC protocol for FVIII visualization, by 
improving blocking efficacy, antibody labelling efficacy and to ensure accuracy and 
validity through qPCR and FC double staining. 
This FC protocol proved its validity and usefulness in visualizing and studying 
functionally FVIII. The project successfully facilitated safe GT protocols in HSC, 
moreover, addressed the need in the field of biomedical research by optimizing a reliable 
FC protocol of staining and visualization of large proteins like FVIII. 
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CHAPTER 1: INTRODUCTION 
1.1. Research Hypothesis 
We hypothesized that a flow-cytometric (FC) analysis for Factor VIII visualization, 
would result in an improvement in the characterization of this protein, particularly in the 
context of Gene Therapy (GT) modification of target cells.  
In order to test our hypothesis, we chose to work on different cells, that can produce 
FVIII in good quantity naturally. 
1.2. Research aim and objectives 
Recent literature suggests that Hematopoietic Stem Cells (HSC) might be an 
efficient target for FVIII replacement through Gene Therapy in Haemophilia A (HA), 
although FVIII is mainly produced in liver. Targeting HSCs as FVIII protein producers 
needs careful quality and safety controls.  
This research project aims to optimize a reliable Flow-Cytometry (FC) analysis to 
characterize FVIII coagulation protein production in cells. The advantage of this method 
is to add functional information, otherwise impossible with currently available 
immunohistochemistry analyses, and to improve the specificity and granularity of data.  
To this aim, the objectives of the project are to: A) Build an extensive background 
through the collection of literature on FVIII production and secretion. B) Validate a FC 
method to visualize FVIII in intracellular compartments and on cell membrane surfaces. 
C) Study FVIII expression and secretion pathways in different cells. D) Evaluate the 
capacity of FVIII protein production in different cells after FVIII gene transduction.  
If successful, this method may be broadly applied to the visualization of FVIII and 
similar large proteins. 
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1.3. Research plan: 
Table 1. The description of the timeline of the project within the year in terms of tasks and dates. 
  
Task description Start Date End date Comment 
Objective 
1 
Literature background 
  
Objective 
2 
RNA extraction, 
Quantitative PCR 
January, 
2017 
March 2019  - 
Objective 
3 
Antibody staining of FVIII  
Task 1 
 
 
Anti-FVIII antibody 
labelling with Dylight 
650 
January, 
2017 
March 2019 - 
Task 2 
 
Antibodies panel 
designing and 
experimental design 
February, 
2017 
To ensure there is 
no spectral overlap 
between antibodies 
used for cellular 
staining. 
Task 3 Performing FC 
experiments on PBMCs 
and the other cell lines 
March, 
2017 
-To stain cells for 
FVIII protein and 
other CD markers. 
Optimizing FVIII 
expression and 
detection by FC. 
-To perform 
functional studies to 
study FVIII. 
Objective 
4 
Results retrieval, analysis, discussion, and finalizing of the written thesis 
by 
April 2019 
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CHAPTER 2: LITERATURE REVIEW 
2.1. Chapter Overview 
The current chapter critically analyses the existing scholarly literature, to explore 
the issues related to the process of coagulation and involved pathways, the epidemiology, 
and pathophysiology of HA, and the specific structure of coagulation FVIII along with its 
role in the process of coagulation. Subsequently, an overview of the Gene Therapy pre-
clinical trials to treat this disorder. Finally, how FC facilitates the characterization and 
visualization of proteins. 
2.2. Coagulation and Clotting Factors: Coagulation Pathway  
Coagulation pathways are complex and diverse and have generally been divided 
into the following types of cascades: intrinsic, standard and extrinsic (Krishnamoorthy et 
al., 2016). Extrinsic pathway of coagulation process has been characterized as the initial 
(first) step in the process of haemostasis, which is mediated by plasma. The process is 
activated by the Tissue Factor (TF), which in turn is expressed within the sub-endothelial 
tissue (Palta et al., 2014). Within the context of standard conditions (e.g., no trauma), 
vascular endothelium serves as a barrier, which prevents (or minimizes) the contact 
between plasma procoagulants on one side and TF. However, during the process of vascular 
injury, TF gets exposed and binds to calcium and Factor VIIa. Such a process triggers 
another critical step, which is the conversion of Factor X to its active form – Xa (Konkle 
et al., 2015). 
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Figure 1. The discussed coagulation pathways: extrinsic, common and intrinsic. (Source: Palta, 
Sarao & Palta, 2014) 
 
 
The intrinsic pathway of coagulation can be described as a pathway, parallel to the 
extrinsic one the critical feature of this pathway is the activation of thrombin by coagulation 
Factor XII. The pathway cascade is initiated by the following components: XII, kininogen, 
HMW, factor XI, and prekallikrein. Their combined action leads to the activation of factor 
XI Once factor XI is activated; it triggers a reaction leading to activation of factor IX. 
Coagulation factor IX, in close interaction with its cofactor – VIII, forms a complex on a 
phospholipid surface, which helps to activate coagulation factor X (Konkle et al., 2015; 
Palta et al., 2014).  
Common coagulation pathway, finally, is the activation path of coagulation factor 
X with tissue phospholipids, calcium and cofactor V. Their interaction leads to the 
formation of the prothrombinase complex, which in turn helps transforming prothrombin 
into thrombin (Palta et al., 2014; Konkle et al., 2015). The obtained thrombin helps to 
cleave further fibrinogen, which is circulating in the bloodstream, and transforms it into an 
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insoluble fibrin form, thus contributing to the formation of the secondary haemostatic plug 
and stabilization of blood clots (Palta et al., 2014)  
2.3. Clotting FVIII: Biochemistry Basis of This Clotting Factor   
Blood clotting FVIII is a non-enzymatic protein serving as a cofactor to activated 
factor IX. It is encoded by FVIII gene in the X-chromosome and specific defects of this 
gene-, which mostly is an inversion mutation in intron 22 of the gene - can lead to the 
development of Haemophilia A disorder (Antonarakis et al., 1995).  
 The FVIII gene has a size of 186 kbp; however, the total length of the coding 
sequence is only 9 kbp (Gitschier et al., 1984). 
FVIII gene has a tissue-specific expression pattern. Due to its large size and the 
complex machinery necessary for translation and secretion, FVIII protein is limited to 
specific tissues, mainly liver cells. Nevertheless, it was reported that FVIII protein has been 
detected not only in liver cells but also in liver resident macrophages, the so-called Kupffer 
cells (Do H. et al., 1999; Zanolini et al., 2015), and several other tissues in the body express 
FVIII mRNA (Su AI, Wiltshire T, Batalov S, et al., 2004). 
FVIII maximum length polypeptide is made up of 2332 amino acids combined in 
six domains A1-A2-B-A3-C1-C2. Localized at the margins of A domains are the acidic 
sub-domains, which have a function in FVIII interaction with other proteins especially the 
thrombin (Gitschier et al., 1984).  
FVIII is homolog to Factor V and other proteins, as MFGE8 protein (Lactadherin), 
which is a milk-fat protein (Figure 3). Both the C domains of FVIII and Lactadherin bind 
to phospholipids. The C2 domain is also crucial for binding to von Willebrand factor when 
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inactive (Lin et al., 2007). A1 and A2 domains are both homologous to the corresponding 
A domains of Ceruloplasmin, the copper- binding protein (Figure 3) (Pasi et al., 2017).  
                                
Figure 2. FVIII protein and FVIII homologs domain structure. The numbers represent homology 
level of amino acids for the domain groups. All proteins shown are from human origin (Source: 
Orlova, Kovnir, Vorobiev, Gabibov, & Vorobiev, 2013) 
 
 
The metal ions - specifically copper - play an essential role in the assembly of FVIII 
chains, which is impossible otherwise (Wakabayashi et al., 2001).  
The transfer of the FVIII protein into the Endoplasmic Reticulum (ER) of the cell, 
leads then to the formation of disulfide bonds, and the attachment of N-linked 
oligosaccharides to the FVIII chain. After the occurrence of N-glycosylation, FVIII protein 
binds to two lectins: Calnexin (CN) and Calreticulin (CRT), and these two lectins function 
in preventing the secretion of immature FVIII proteins (Pipe et al., 1998). The immature 
protein that needs to be further processed bound with Calnexin and Calreticulin is usually 
transferred to the Golgi apparatus where it goes through processing (glycosylation, 
sulfation and proteolytic processing) (Figure 4). The unfolded proteins remain in the 
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endoplasmic reticulum for re-glycosylation and undergo again through the Calnexin cycle 
(Pipe et al., 1998). 
 
Figure 3. FVIII protein Intracellular trafficking before secreted. Membrane-protein translocators 
OST and Glucosidases GI and GII. Then, Calnexin and Calreticulin are bound to the chain 
(Source: Orlova et al., 2013). 
 
 
As FVIII protein is in the lumen of Endoplasmic Reticulum, it forms a complex 
with the so-called Immunoglobulin Binding Protein BiP, which is a significant chaperone 
of the Endoplasmic Reticulum. This chaperone is a critical component of the Unfolded 
Protein Response signaling reaction or pathway (UPR). During cells stress, like in case of 
starvation of sugars/glucose where N-glycosylation is inhibited or in case of 
overexpression of FVIII protein, the amount of misfolded proteins inside the ER increases, 
and the synthesis of BiP in high amount is induced (Dorner et al., 1989; Brown et al., 2011) 
and the complex of BiP with FVIII protein leads to its retention in ER. The adequately 
folded FVIII protein is transported from the Endoplasmic reticulum to the Golgi apparatus 
through intermediate structures known as ER-Golgi intermediate compartment ER-GIC, 
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clearly shown in Figure 3. After that, FVIII protein gets ready to be secreted outside of the 
cell (Dorner et al., 1989). 
Additionally, the production of FVIII in “professional producer” cells like 
endothelial cells is supported by a more organized structure: FVIII is stored in cigar-like 
shaped organelles, known as Weibel-Palade bodies (WPB), and released FVIII upon 
specific cell stimulation.  
Finally, Von Willebrand factor (vWF) is a multimeric glycoprotein that plays a key 
role in FVIII lifecycle. The protein is synthesized mainly in the endothelium and 
megakaryocytes, and its synthesis contributes to WPBs formation where FVIII is stored. 
VWF guides the trafficking of FVIII inside the cells (Wagner, 1990) and is secreted 
in the bloodstream, where it binds to FVIII, protects it from degradation, from unspecific 
activation, and directs FVIII to sites of platelet plugs, facilitating adhesion and subsequent 
clot formation (Wise RJ, Dorner AJ, Krane M, et al. The role of von Willebrand factor 
multimers and pro-peptide cleavage in binding and stabilization of FVIII. J Biol Chem. 
1991; 266:21948–55).   
 
2.4. Clotting FVIII: Mechanism of Action 
The process of FVIII activation is central to the process of blood coagulation. FVIII 
is synthesized in the form of a single polypeptide forming two chains, consisting of the A1 
– A2 domains (heavy chain), and the A3 – C1 – C2 domains (light chain). The chains are 
linked by the B domain, that is detached before secretion. The activation in FVIIIa takes 
place after secretion, through cleavage of the secreted protein and detachment from vWF 
chaperone (Figure 5 B). The C2 domain has an essential function in membrane association 
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through the binding of phospholipids. A deletion in this region can lead to complete 
abrogation of FVIII binding to the platelets surface (Konkle et al., 2015). 
 
 
 
The coagulation cascade along with the FVIII and its role in it is graphically 
represented in Figure 4. As discussed earlier within the chapter, the coagulation process 
features two distinct pathways (intrinsic and extrinsic) (Figure 5 A), both triggered 
(activated) via exposure to tissue factor (TF). Activated platelet membranes can also 
expose phosphatidylserine groups (PS) that can also activate both pathways. After being 
activated via proteolytic way, for example by thrombin FXa, FVIII undergoes dissociation 
from VWF and creates an association with the FIXa, which is a serine protease (Palta et 
al., 2014). FVIII is responsible for directing the localization of the complex that has been 
formed to the membrane surface of platelets that have been activated. The latter are 
activated via interaction with the C2 domain of the complex (Figure 5 A).  The complex 
between FIXa and FVIIIa (membrane-bound) has a crucial function: to activate Factor X 
via proteolytic way, which in turns triggers the activity of thrombin (Palta et al., 2014).  
Within human blood, FVIII circulates as a part of a stable complex with von 
Willebrand Factor. Once thrombin (also known as factor IIa) is activated, it activates FVIII 
and the complex begins interacting with element IXa. Such a process is known as the 
coagulation cascade. Factor IXa takes part in the activation of another coagulation factor – 
X. Cofactor X has been shown to act as a cofactor to factor Va, which has the power to 
activate more thrombin (Pasi et al., 2017). Thrombin, furthermore, can cleave fibrinogen 
which transforms into fibrin. Fibrin has a unique ability for polymerization and 
  
 
10 
 
crosslinking (via the assistance of factor XIII), which eventually results in the formation of 
blood clots (Pasi et al., 2017; Krishnamoorthy et al., 2016). As FVIII is no longer attached 
and protected by vWF, it undergoes the process of proteolytic inactivation. Protein C and 
factor IXa are involved in inactivating FVIII and quickly removing it from the human 
bloodstream.  
 
2.5. Clotting FVIII: Site of Production 
As of now, the primary site of FVIII release is considered to be ambiguous (Pasi et 
al., 2017); however, it is known that it is produced and released into the human bloodstream 
from tubular, glomerular and vascular types of endothelium.  
The liver is the main site for FVIII production, specifically in liver sinusoidal 
endothelial cells, that are layered at the interface with hepatocytes and the blood stream in 
the sinusoids of the liver (Do et al., 1999). Furthermore, Konkle et al. report that 
Haemophilia Type A has been known to be corrected among patients who have undergone 
liver transplantation procedure.  
Nevertheless, based on literature evidence, there are also other sources of FVIII 
production or secretion, so-called extra-hepatic FVIII sources. Different tissues and organs 
have been identified as FVIII producers, as monocytes, macrophages, kidney, and lung 
(Hollestelle et al., 2000; Groth et al., 1974; Zanolini et al., 2015; Jacquemin et al., 2006). 
Similarly, it is proven that HSC transplantation can correct HA in mice, providing evidence 
that HSC or their progeny can produce functional FVIII (Follenzi et al., 2004).  
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2.6. Haemophilia A: Genetic alterations and pathophysiology 
1. Genetic mutations in HA  
HA is a genetically inherited bleeding disorder, characterized by the lack or 
deficiency of Coagulation FVIII. FVIII first characterization was in 1994 by Genentech 
scientists (Gitschier J et al., 1994). The FVIII gene is on the X chromosome at position 
q28. HA is an X- linked recessive disease, affecting therefore males with the overt disease, 
while affecting females predominantly with mild traits or a silent carrier status. The genetic 
aberrations are normally inherited, but may also arise from de-novo mutations, accounting 
for a 30% of sporadic (not-inherited) HA cases (Kasper & Lin, 2007). 
Incorrect and abnormal biosynthesis and secretion of clotting factors can be a direct 
result of different defects. Importantly, gross rearrangements and deletions can lead to 
abnormal DNA transcription, RNA processing and alter the process of translation (Konkle 
et al., 2015). The deficiencies in quantity or functioning of FVIII arise from various genetic 
mutations, including intron 22 inversion, gross deletions, point mutations, missense 
substitutions and splice site defects. Such gene mutations lead to the inability of an 
organism to create a fully functional FVIII protein or the inability to synthesis any FVIII. 
Therefore, no effective and operational blood clots can be produced to repair the damaged 
blood vessel walls in case of an injury (Peyvandi et al., 2016). 
According to Palta et al., minor gene defects such as single missense mutations can 
also result in defective secretion of FVIII. Empirical evidence suggests that such mutations 
commonly occur within a specific codon – 2307 – and are caused by the replacement of 
Arg by Leu or by Gln. The proteins created after translation appear to be normal as far as 
their function, however, display poor secretion patterns and therefore cannot effectively 
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contribute to the process of coagulation. Importantly, there is growing evidence that defects 
associated with functioning and production of the FVIII may not be limited to the FVIII 
gene itself.  
Moreover, deficiency of factors V and VIII registered among some hemophilic 
patients has been linked to gene defects that lay outside of the FVIII gene, and instead – 
located on chromosome 18 between the genetic markers D18S1103 and DD18S849 
(Konkle et al., 2015). 
2. Clinical features and diagnosis. 
As a clinical condition, haemophilia can be manifested via spontaneous and 
traumatic bleeding. The pathophysiology of the condition is closely associated with 
abnormally low levels of FVIII, or its significantly reduced level of activity. 
The process of diagnostics of haemophilia is focused on the identification of 
clinical symptoms and analysis of the concentration of the coagulation factor in patient`s 
blood and plasma (Pasi et al., 2017). Depending on the concentration of the coagulation 
factor, the observed bleeding disorder can be classified as either: mild (5 – 40% of standard 
concentration), moderate (1 – 5% of normal concentration), and severe (less than 1% of 
normal concentration).  
3. Treatment. 
The specific treatment plans and interventions depend on the severity of the 
symptoms, genetic make-up, and possible complications and associated comorbidities – 
the co-occurrence of more than one health condition or diseases (Al-Tonbary et al., 2010).  
The key modern healthcare approach towards treatment and management of HA 
offers a protein replacement therapy, with recombinant FVIII. Pasi et al. (2017) discuss a 
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common complication among patients undergoing such treatment, which is the 
development of neutralizing antibodies. These antibodies arise against the FVIII protein 
that is being introduced into a patient`s body during the treatment, in a scenario, where the 
immune system might recognize the protein for the first time. Collectively, nearly 30% of 
all the patients diagnosed with severe haemophilia, A and 3-13% of patients with mild-
moderate forms develop such alloantibodies, capable of inactivating coagulation FVIII, 
and as a result – nullify the replacement therapy (Pasi et al., 2017). Such a phenomenon 
has negative consequences for the patient`s health and makes haemophilia treatment highly 
complex, requiring alternative long-term efficient therapies, such as cell and GT 
approaches (Krishnamoorthy et al., 2016).  
2.7. Epidemiology of HA: Global Perspective and Gulf Region 
Among the Inherited Blood Disorders (IBDs), haemophilia has been described as 
the most common type. The two haemophilia types A and B have been demonstrated to 
impact one in every 5000 and one in every 50,000 males worldwide respectively (Al-
Tonbary et al., 2010). Some risk factors have been identified that determine the 
epidemiology of the disease. First of all, due to the genetic nature of inheritance, family 
history of haemophilia is a key risk factor (Pasi et al., 2017; Shen et al., 2008; Peyvandi et 
al., 2016). Secondly, due to the specific genetic inheritance male gender can also be 
regarded as a risk factor.  
The phenomenon of X chromosome inactivation (or lyonization) defined as the 
inactivation of two out of three random X chromosomes in the human cell, contributes to 
such prevalence rate of HA among the female population (Wight & Paisley, 2003). 
Importantly, there is the third type of haemophilia known as haemophilia type C, or 
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“acquired haemophilia”, which affects both genders and ethnic groups in equal proportions 
at the rate of 1/1,000,000 persons and is manifested by the body producing antibodies that 
target FVIII (Shen et al., 2008, Wight & Paisley, 2003 Collins PW, 2011). 
 The acquired form can be due to inflammatory bowel disease, hepatitis, pregnancy 
and the postpartum period, diabetes, etc. (Peyvandi et al., 2016)  
According to the argument presented by Konkle et al. (2015), genetic factors, as 
well as cultural differences, may contribute to epidemiological patterns of haemophilia 
distribution worldwide. For example, within Egypt where the local population has reached 
80 million people, consanguineous marriage is a widespread phenomenon. This leads to 
more individuals being born with autosomal recessive coagulation diseases and an overall 
high prevalence of haemophilia when compared to the rest of the world (Al-Tonbary et al., 
2010; Krishnamoorthy et al., 2016). 
Reports about the frequency of different types of haemophilias -including type A- 
in the Middle East in general and Gulf Region Countries in particular, are very scattered. 
For instance, Awidi conducted longitudinal research to explore the frequency and severity 
of various IBDs within Jordan. According to the obtained results, HA, Von Willebrand 
Disease, and Glanzmann thrombasthenia are the most frequent disorders in Jordan, with 
10% of haemophilia A patients experiencing haemophilia inhibitors (Awidi, 2006). Abu 
Amero implemented the first systematic sequencing effort of various haemophilia-related 
gene abnormalities among Arab patients in Qatar to investigate FVIII mutations spectrum. 
According to the obtained results from this pilot study conducted on 20 patients, patients 
displayed a range of FVIII mutations, among, which 22 intron inversion was the most 
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common mutation impacting nearly 55% of the patient population, (11 out of total 20 HA 
subjects) in range with the worldwide described genetic distribution (Abu Amero, 2008).  
 
 
2.8. GT approach for the treatment of HA 
Due to the reasons discussed above, scientists are focusing on advancing 
therapeutic platforms for HA, to ensure a long lasting and efficient treatment. (Nienhuis, 
Nathwani, & Davidoff, 2017). GT can be a fascinating approach for treating HA for the 
reasons that: a) this disorder is monogenic, which makes it a good target for GT, b) different 
cell types in the human body are capable of synthesizing functional FVIII protein meaning 
that different cell types can be targeted for gene transfer, and c) GT is more economical 
and less time consuming than the protein replacement therapy, which is expensive, it 
requires multiple infusions of the recombinant protein and – as discussed before - can lead 
to the risk of developing anti-recombinant FVIII antibodies (Dimichele, 2002).   
Several studies are focused on hepatocytes as a target for GT approach to correct 
hemophilia as the liver is known for being the primary source for coagulation factors 
production. GT targeting liver was tested by IV infusion of adeno-associated virus (AAV) 
vectors that successfully showed outstanding efficiency in correcting HA in dogs (Finn et 
al., 2010). Not only in canine models, clinical trial showed that AAV vector had a high 
efficacy in transducing hepatocytes and showed long term of expression of clotting factors 
in severe haemophilic patients (Rangarajan S et al., 2017). However, due to the 
immunogenicity of the liver, using IV infusion of AAV vectors directed to hepatocytes can 
lead to immune-mediated reactions, through T-cell responses (CD8+) directed to the AAV 
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capsid. The hallmark of this event is the elevation of liver enzymes  (Mingozzi et al., 2007), 
and this alteration is tightly monitored in clinical trials, since it is the first sign of immune-
rejection of the GT product. Patients with liver enzymes alterations have to undergo cycles 
of high-dose immune suppressive therapies, to promptly stop this immune trigger. 
Therefore, scientists are working on different viral vectors not only to improve the efficacy 
of the gene transduction but also to improve the immunogenicity profile. 
 
Figure 4. The coagulation cascade and the role and structure of FVIII (source: Shen et al., 2008) 
 
Lentiviral vectors (LV) are less immunogenic in comparison with AAV, and at the 
same time, their capacity for transgene cassette expression is suitable for a large gene like 
FVIII. To solve the problem of high immunogenicity, parallel pre-clinical work is ongoing 
to test the gene correction through LV targeting other tissues, more immune-privileged than 
liver. FVIII LV mediated ex-vivo GT using mobilized peripheral blood CD34+ HSC with 
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a CD68 monocyte specific promoter showed a sustained FVIII production in an 
immunodeficient murine model without signs of toxicity (Doering, et al., 2018). 
CD34+ HSC cells have been proven an optimal target of GT correction in several 
disease models, as ADA-SCID, Fanconi Anaemia, Wiskott-Aldrich Syndrome and Beta-
Thalassemia (Donnelly, Zelterman, Sharkis, & Krause, 1999). Once gene corrected, these 
cells give rise to a stable gene modified progeny, that is long-lasting. So far, the longest 
patients’ follow-up of are about 20 years in SCID diseases, but potentially the correction is 
lifelong.  
In HA is not clear which HSC-derived lineage is producing FVIII, other than 
megakaryocytes, and myeloid-derived Kupffer cells, although these evidences and the 
scientific achievements in HA phenotype corrections in mice after CD68 targeted GT, 
collectively point to the myeloid lineages (Doering, et al., 2018).  
While targeting the HSC population with gene modifications is necessary to 
maintain a stable transgene production, the choice of the best final target cell is needed in 
HA, since FVIII off-target expression might be toxic for the cells and for the whole body 
(Merlin, et al., 2017). 
There are some hurdles in the field of GT, one of them is the insertional mutagenesis 
which is the case that the DNA is integrated in a certain spot within the genome for instance 
in a tumour suppressor gene, this can lead to cancer development which increases the harm 
to the patient. This occurred in clinical trials for X-SCID leading to some patients about 
15% developing leukaemia after receiving GT treatment of stem cells transduced with 
curative gene (Thrasher AJ, et al. 2006).  In addition to the hurdle of durability of GT 
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benefit. Therefore, careful monitoring of the results of GT treatment by proper analysis 
needs to be implemented. 
Noticeably, a Flow-cytometry (FC) platform for the visualization of FVIII protein 
in blood cells would be the best option to advance in this field, both in the discovery of the 
best GT target cell, and to assess GT results in such target cells.  
 
 
2.9. Flow-Cytometry: A Method to Visualize and Characterize Proteins  
 Flow cytometry is a clinical chemistry technology that analyses single cells based 
on their fluorescence and optical characteristics.  Physical properties, like internal 
complexity and size, which affect how light is scattered in this technology, can be used to 
determine certain cell groups (Pandey et al., 2013). In flow cytometry, a laser emits a beam 
of monochromatic light through the cells in a fluid sample, and the cells further give off 
the light in all directions. Optics, in the flow cytometer, direct the given off light to dichroic 
mirrors and an array of filters that sequester specific wavelength bands, therefore, resolving 
cell populations (Pandey et al., 2013). 
 Flow-Cytometry recently started gaining popularity and preference by many 
cancer therapists, immunologists, and even gene-therapists. Flow-Cytometry is a complex 
instrumental measurement for multiple physical properties of a cell (Figure 5). 
 It can assess cell’s size, granularity and different proteins expression and 
characterize therefore cells phenotype trough CD antigen markers/expression/secretion of 
individual molecules. All these parameters are measured simultaneously as the cells in fluid 
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suspension is flowing through the cytometry device (Adan, Alizada, Kiraz, Baran, & 
Nalbant, 2017).  
 
 
Figure 5. A scheme of FC and a sample showing Flow-Cytometric analysis of data: A) a 
suspension of cells moving through the sheath fluid to the flow cell in, which a laser beam hit the 
cells leading to light scatters (FSC: forward scatter and SSC: side scatter). B) An example of 
analysis of CD4+ T cells that are also positive for FOXP3+. (Source: Jaye, Bray, Gebel, Harris & 
Waller, 2012) 
 
 
Cells are usually labelled with fluorescent dyes or with fluorescent monoclonal 
antibodies before being analyzed by FC. While flowing in the machine, cells move in a 
sheath fluid and their physical and fluorescent properties are captured by the device within 
small sheat-fluid droplets; each droplet is a single cell.  
Forward scatter (FSC), reflects cells’ size and Side scatter (SSC) reflects granularity 
and complexity of cells. In addition, the fluorescent light emitting from the antibodies 
bound to the cells are detected form the Fluorescence channels (example: FL1 in Figure 5) 
of the machine.  
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The field of FC has grown considerably for the last three decades both in the areas 
of research and clinical diagnostics, as shown by the number of articles in the medical 
literature involving FC (Figure 6).   
 
Figure 6. Representation of FC main milestones: a bar graph showing the critical FC development 
events. (Source: Jaye et al., 2012). 
 
 
 Flow-cytometry analysis as a methodology has several advantages over other 
methods such as immunohistochemistry or Western blotting in terms of functional 
assessment and characterization of all types of cells. The benefits of FC can be summarized 
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as flexibility, reproducibility, increased specificity and most of all, the possibility of 
function evaluations.   
Therefore, an FC protocol optimized and validated for the visualization of FVIII 
protein would be an excellent option to assess the efficiency of HA Cell and GT trials, 
particularly for blood cells, but also for any FVIII containing cell. Of note, such method 
would also open unprecedented diagnostic potentials for HA patients. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1. Materials 
Cells used: 
U937 (human pre-monocytic) cells, HECV (human vascular endothelial) cells were 
received as a kind gift from Antonia Follenzi, Health Sciences Department in Piemonte 
Orientale University in Novara-Italy. HELA cells (cervical cancer) were purchased from 
American Type Culture Collection (ATCC™), USA. PBMCs purchased by AllCells (Ca, 
USA).  
Cell culturing media for this project were IMDM, and Advanced RPMI purchased 
from Gibco™, USA. Foetal Bovine Serum (FBS) used is from Sigma Aldrich™, USA. 
Trypsin for adherent cells was TrypLE Express Enzyme from Gibco™, USA.   
Antibodies used: 
Anti-FVIII monoclonal antibodies (GMA8002 against the A1 domain of the FVIII 
protein and (GMA8024) against the A2 domain of the FVIII protein were purchased from 
Green Mountain Antibodies™, USA. Corresponding IgG isotype controls: IgG2a and IgG1 
from Roche diagnostic™. Anti-CD19: PerCP Cy5.5, anti-CD33: PE-Cy7) anti-surface 
markers antibodies were from BioLegend™.  
FC analysis kits used: 
Two main kits for antibody labelling were used: 1) Dylight 650 NHS Ester™, 
Thermo scientific (the custom antibody labelling kit), 2) Zenon™ Alexa Fluor Mouse 
Labelling Kit (Zenon antibody labelling with different colours: AF647, AF488, and 
AF568), Invitrogen. Mouse serum for staining was from Life Technologies™. The FC 
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staining was performed based on the manufacturer’s protocol of the fixing and 
permeabilization of cells of the BD Cytofix/Cytoperm™ staining Kit. Thermo Fisher 
Scientific LIVE/DEAD™ Fixable violet Dead Cell Stain kit was utilised. FcR Blocking 
Reagent was from Miltenyi Biotec™ and Human MFGE8 or Lactadherin was from 
Avivasysbio™.  Lactacystin (26S proteasome inhibitor) was purchased from Sigma 
Aldrich™, USA.  
RNA extraction and quantitative PCR kits used:  
As for the RNA isolation and qPCR, for RNA extraction using Invitrogen™ RNA 
isolation kit, cDNA synthesis cDNA using reverse transcription GoScript™ Promega kit 
and qPCR was done using GoTaq kit from Promega™.   
Gene transfer viral vector used: 
The viral vector used is a Lentiviral Vector carrying the Beta-deleted FVIII protein 
gene cassette, under PGK promoter (Self-Inactivating (SIN) 3rd generation LV 
hPGK.hFVIIIBDD). This viral vector was a kind gift from Antonia Follenzi, University of 
Piemonte Orientale, Italy.  
 
3.2. Ethical approval of the research work 
This study was performed in a laboratory with an ethical approval for biosafety (IBC 
approval) from Qatar Biomedical Research Institute-Doha, Qatar. The protocol number 
of the approval is IBC/2016/009.  
 
3.3. Cell cultures and maintenance of cell lines 
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Two adherent types of cell lines were used in this project: HECV, which are human 
vascular endothelial cells and HELA, which are cervical cancer cells. These cells were 
cultured in IMDM with 10% and 1% (v/v) FBS and Penicillin/Streptomycin respectively 
(complete medium). Cells were trypsinized once a week with this method. Media was 
removed by aspiration from the cells; cells were washed with 1X PBS and then detached 
by incubation for 5-8 minutes with 1 ml of TrypLE Express Enzyme, which is a gentle 
trypsinizing solution. Media was then added to cells with FBS to inhibit/stop the trypsin, 
and then cells were collected from flasks, counted using Trypan blue viability stain and 
microscopy, centrifuged at a speed of 300g for 5’ and split (typically ¼ of the volume) into 
new flasks with fresh media. 
The non-adhering human pre-monocytic cell line U937 was also used in this 
research. U937 cells were cultured in Advanced RPMI complete medium. Cells were 
counted using Trypan blue viability stain and microscopy, and a specific number of cells 
were passed (typically ¼ volume of cells) into new flasks with fresh medium. Cells were 
incubated at 37 degrees, 5% CO2 incubator. PBMCs were used both either directly after 
thawing or after an overnight culture with complete medium. Cells for experiments were 
used at a normalized fashion to always be 1x106  cells/conditions, if not otherwise specified. 
 Cell culture with Lactadherin (milk fat globule) was performed with 4 nM 
Lactadherin incubated with seeded cells in 24-well culture plates for overnight to block the 
cells and prevent FVIII stickiness to the cells’ membrane. The next day, cells were 
harvested and immune-stained for FVIII to detect FVIII expression intracellularly and 
extracellularly.  
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FVIII protein degradation via proteasomal pathway was assessed by FC after 
proteasome inhibition by 50µM Lactacystin incubated with cells for 4 hours cells at 37 
degrees, 5% CO2. After the incubation time, FC was performed on these cells according to 
staining kit manufacturer’s protocol. 
 
3.4. Flow cytometry for cells 
Cells were normalized for all FC experiments to be divided into 1 million 
cells/condition. Then, cells were washed once with PBS for LIVE/DEAD Fixable Dead 
Cell Staining, performed for 15’ in the dark at RT. Cells were then washed with staining 
buffer (BSA-PBS solution) at 300g for 5’. Surface staining using (anti-CD19: PerCP Cy5.5, 
anti-CD33: PE-Cy7) anti-surface markers antibodies to the cells with staining buffer done 
with 20’ in 4 degrees’ fridge incubation and then cells washed once with staining buffer. 
Cells were thoroughly re-suspended in fixation buffer and incubated for 15-20’ at room 
temperature.  
Cells were then washed and re-suspended in permeabilization buffer along with the 
fluorescently labelled anti-FVIII antibody and incubated for 15’ at room temperature. Cells 
were then washed twice with staining buffer at 300g for 5’and resuspended in 
paraformaldehyde and read on the flow cytometer. The staining was performed according 
to the manufacturer’s protocol steps of the staining FIX & PERM (Molecular Probes™) 
kit. 
For more specific details on labelling method, see also Table 2, Section Results. 
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3.5. RNA extraction and Quantitative PCR  
Some cells were dedicated for mRNA extraction that was performed using RNA 
extraction from Tissues kit from Thermofisher scientific according to manufacturer’s 
procedures. Cells harvested from the cell culture were centrifuged at 300g for 5’ to pellet 
the cells. Media was discarded and cells were resuspended in RNALater buffer and placed 
in 4-degree fridge. RNA was extracted in the laboratory fume hood. After mRNA was 
isolated, synthesis of cDNA from RNA was achieved through using the high capacity kit 
for cDNA reverse transcription kit GoScript™ Kit from Promega™. Following cDNA 
synthesis according to the kit’s protocol, cDNA was stored at 20- degrees’ freezer.  
Quantitative PCR was performed using 96 well plates. The plate was set up with 
RNAse/DNase free water, the kit’s Master Mix, the deoxynucleotide Triphosphates 
(dNTPs), the Taq polymerase, and the primers for FVIII according to manufacturer’s 
protocol. The following hFVIII specific primers were used: (Forward Sequence: 
CCAGAGTTCCAAGCCTCCAACA; Reverse Sequence: 
GGAAGTCAGTCTGTGCTCCAATG) for evaluating the FVIII transcripts (Carol Miao 
et al., 2015).  
Samples were usually run in duplicate and results expression is relative to 
expression of GAPDH housekeeping gene (GAPDH Forward Sequence: 
TGCACCACCAACTGCTTAGC; Reverse Sequence: 
GGCATGGACTGTGGTCATGAG). Controls were utilized and samples were analysed in 
replicates in order to ensure results’ consistency and accuracy. 
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3.6. Viral vector transduction 
Cells were harvested and counted by Trypan blue and haemocytometer. The cells 
were seeded in culturing plates as 500,000 cells per well. Cells were transfected with the 
Lentiviral vector carrying the FVIII gene cassette at two different Multiplicity of Infection 
(MOI): 5 MOI and 30 MOI. The cells were transduced with the viral vector for 24 hours. 
On the second day, cells were washed to remove the virus and cells were cultured normally. 
 
 
3.7. Data analysis  
FC data were analysed using FlowJo version 8.5 and Kaluza softwares. Quantitative 
PCR data were analysed by Roche Light Cycler software, the data were analysed using the 
double delta Ct analysis using Ct values of the housekeeping and FVIII genes. Moreover, 
the statistical analyses were done using GraphPad Prism and Microsoft excel software in 
which the type of test that were used to check significance of results is by using Student’s 
t-test to compare means and the results were shown or represented as Mean+/- SEM. 
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CHAPTER 4: RESULTS 
4 Optimization of The Flow-Cytometry Staining Procedure for FVIII 
Visualization: 
This project is aimed at optimizing and validating a FC staining protocol that can serve 
as a tool for FVIII characterization. To successfully do this, as a first step, we stained 
PBMCs using anti-FVIII and IgG2a antibodies labelled with Dylight 650 NHS Ester™. To 
visualize FVIII in cells, custom labelling was performed for GMA anti-FVIII antibodies 
against different FVIII domains with the labelling kit Dylight 650 NHS Ester™.  
 
4.1. FVIII detection in PBMCs using FVIII and IgG2a Dylight 650 NHS 
Ester™ labelled Antibodies  
Murine anti-human FVIII antibody (GMA™ 8002), specific to A1 domain of the 
FVIII protein in addition to a parallel IgG2a isotype control were labelled in-house using 
Dylight 650 NHS Ester™ labelling kit and the labelling was done based on the 
manufacturer's procedural protocol.  
Peripheral Blood Mononuclear Cells (PBMCs) were then stained with AF647 
custom labelled anti-FVIII or IgG2a control antibodies, at 1 million cells/condition both 
for surface (by staining without permeabilizing the cells) and intracellular staining, after 
1% of Mouse serum blocking in staining buffer to reduce non-specific antibody binding. 
For surface staining anti-CD19: PerCP Cy5.5, anti-CD33: PE-Cy7 were added as well to 
distinguish PBMC sub-fractions. 
After the staining, the FVIII percentage was measured using flow cytometer and 
staining showed high positivity of both FVIII and the IgG isotype control, suggesting high 
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non-specific binding of anti-FVIII antibody to the extracellular and intracellular 
compartments of PBMCs (Figure 7).  
 
 
 
 
4.2. Competition assay to assess specificity and binding (competition with 
recombinant FVIII protein)  
Due to the results of the first experiment an experiment to assess the antibody’s 
specificity was performed. Dylight 650 NHS-labelled anti FVIII and IgG2a antibodies 
were co-incubated with recombinant FVIII protein before labelling, hypothesizing a 
reduction in the staining due to saturation of the specific binding sites. 
(A) 
(B) 
0.16 7.42 8.90 2.95 2.59 
0.00 7.91 7.79 84.7 87.6 
Figure 7: FC analysis for PBMCs stained for FVIII using Dylight 650 NHS labelled anti-FVIII antibodies 
showing un-specificity staining patterns. Cells shown here were stained for surface marker CD19 (shown the 
plots in panel A upper row) and CD33 (shown the plots in panel B below row). 
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In this assessment experiment, PBMCs were washed once with staining buffer. Cell 
blocking was done with 1% mouse serum in staining buffer with cells and the other staining 
conditions were kept as above. The detailed scheme of experiment follows in Figure 8. 
 
 
Figure 8: Schematic representation of the FC experiment performed on PBMCs to study the 
behavior of the FVIII protein and the specificity of the antibody. 
 
 
By pre-incubating the antibody with the protein, the contrary occurred than what 
was expected: the cells stained with the mix of anti-FVIII antibody and FVIII protein had 
the highest FVIII percentage of positivity (Fig 9). These data confirmed that the abundance 
of FVIII protein was binding non-specifically to the cellular membrane. 
FVIII has domains (C2 domain mainly) that are involved in the stickiness or 
aggregation property of the protein to the phosphatidyl serine parts (o-phospho-L-Serine) 
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or (PS) of the cell membrane. Therefore, it is very likely that as cells were permeabilized 
and incubated with recombinant FVIII protein; the protein was aggregating to the 
membrane in the PS regions leading to the antibody unspecific binding as shown in the 
results. 
Moreover, antibodies’ Fc regions can bind to the PBMCs Fc receptors, very 
abundant especially in dendritic cells and monocyte/macrophages. This highlighted the 
need for proper and adequate blocking steps in order to mitigate for the un-specific 
binding of the antibodies and for the adhesiveness of the protein.  
 
 
  
Figure 9: Dot plot of the FC experiment for FVIII assessment. Showing the data of the competition assay.  
As shown clearly. Pre-incubation of PBMCs with recombinant FVIII protein led to increase in staining. 
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4.4.Comparison between Fc Block Vs. Mouse serum block efficiencies in 
reducing the intracellular non-specific binding using PBMCs and use 
of IgG1 isotype control 
The next experiment was done to mitigate the unspecific binding of antibodies; 
therefore, we assessed the efficiency of Fc blocking with increasing concentrations versus 
the efficiency of mouse serum blocking. Also, this experiment was done to compare 
between IgG1 isotype control versus IgG2a isotype control. 
The FC was performed on PBMCs, stained using the same procedure with either: 
IgG2a or IgG1 isotype labelled with AF647. The Fc blocking (at different concentrations) 
and mouse serum blocking (10% concentration) were examined. The conditions of the 
experiment were: Negative (Unstained, fixed), live and dead staining only, IgG2a + mouse 
serum 10% (v/v) + Fc 2.5 µg; IgG2a + Fc 2.5 µg; IgG2a + Fc 5 µg; IgG2a + mouse serum 
10% (v/v), IgG1 + Fc 5 µg. All conditions except the negative conditions were stained for 
CD14 BV421 and CD 8 PE. 
Mostly monocytes were affected by high un-specificity. This is due to high 
autofluorescence and to the abundance of Fc receptors. Indeed, increasing concentrations 
of Fc blocking showed a partial correction of un-specificity (Figure 10 panel A and B).  
However, addition of 10% Mouse Serum blocking showed even neater staining 
without FC block (panel C). Adding 10% MS to 2.5 mg FC block did not increase the 
efficiency of MS alone (panel D). This indicates that MS is per se efficient enough to block 
Fc receptors.  
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Finally, substituting IgG1 to IgG2 showed clearly a drastic reduction in the 
background staining (panel E). Thereafter, Mouse Serum 10% block was consistently 
added to every experiment and IgG1 preferred as control instead of IgG2. 
 
 
   
 
  
Figure 10: FC experiment for comparison of different blocking types: comparing the efficacy of different 
concentrations of Fc blocking (Panel A 2,5 µg/100 µl buffer, Panel B 5 µg/100 µl buffer, Panel C Mouse 
serum 10% final concentration, Panel D 2,5 µg/100 µl buffer and panel E IgG1 isotype control. 
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4.5. Zenon technology for labelling of the anti-FVIII antibody 
We compared to custom labelled antibody another labelling method for anti-FVIII 
antibody: The Invitrogen Zenon™ Alexa Fluor 647 Mouse IgG1 Labelling Kit.   
The Zenon labelling technology can provide high specificity, and a time-sparing 
protocol - as the labelling can be done within minutes - and reliability of results.  The 
technology of Zenon uses Fab fragments that are fluorophore-labelled against Fc of a 
primary antibody (Anti-FVIII antibody) to form the labelling complex (Fig. 11).  
 Therefore, the labelling reagent directly stains the target antibody with 
fluorophore-labelled Fab fragments. The FC experiment data are showing how the staining 
with Zenon can be more specific than the stable labelled dye in PBMCs. (Fig. 12).  
 
 
 
 
 
Figure 11: Zenon labelling technology for antibodies: the illustration is showing the principle of this 
technology of antibody labelling. 
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Figure 12: FC dot plots of PBMCs: PBMCs were stained with the anti-FVIII and IgG1 isotype 
control both labelled with the Zenon labelling kit for AlexaFluor 647. As shown, the staining 
quality is improved with the Zenon technology giving less un-specific binding and more clean 
staining of cells. 
 
 
4.6. FVIII FC visualization on cell lines 
To verify if FC FVIII visualization was broadly applicable to various cell types and not 
only restricted on blood cells, we tested different cell lines with this staining.  
We chose HECV endothelial cells, as “professional” FVIII producers’ cells, since FVIII is 
mostly produced by liver sinusoidal cells. We selected then HELA cancer cell line, being 
the cervical tissue rich of FVIII mRNA (Su AI, Wiltshire T, Batalov S, et al., 2004). We 
also included U937 cells: a pre-monocytic cell line, representative of myeloid blood cell 
capacity for FVIII assembly and production (Zanolini D, Haematologica 2015). 
We first confirmed the mRNA content of the cell lines through quantitative RT-PCR. 
FVIII mRNA was measured against the housekeeping gene primers for GAPDH. 
Expression of FVIII mRNA was tested after RNA isolation, cDNA synthesis and then 
cDNA amplification through quantitative PCR (qPCR). FVIII expression in the different 
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cell lines is shown below. FVIII protein was successfully visualized in all 3 cell lines, as 
shown in various experiments listed below. 
 
 
 
 
Figure 13: FVIII mRNA expression in un-transduced (UT) HECV, Hela and U937 cell lines. 
 
 
4.7. FVIII Visualization Gating Strategy 
FVIII protein visualization was as well enhanced by consistently using the following 
stringent logical gating strategy which is illustrated clearly in the below figure of FVIII 
visualization in U937 cells (Fig. 14). The logical gating starts by defining the cell 
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populations strictly on the FSC/SSC parameters, then to exclude doublet cells and select 
singlets only on FSC-A/FSC-H parameters, and further exclude dead cells/debris, 
enriched of cell membranes non-specifically bound to FVIII molecules through PS 
exposed sites. Finally, FVIII positivity gets compared to the appropriate IgG isotype 
control. 
 
 
 
Figure 14: Gating strategy for FC analysis for FVIII. Illustration of the gating strategy used for 
FC analysis of U937 cells stained with anti-FVIII antibody labelled with Zenon AF647. 
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4.8. Different cell confluence interplay with FVIII expression in HECV 
and HELA  
Cell confluence can have its impact on the expression of proteins by cells such as 
FVIII protein because high confluence may inhibit protein production. The confluence of 
cells and its interplay with FVIII expression was carefully assessed using 2 adherent cell-
lines: HECV, and HELA cells. The cells were divided into several culture flasks with 
different confluence rates:  50% HECV cell culture flask, 50% HELA cell culture flask, 
80% HECV cell culture flask, and 80% HELA cell culture flask.  
Then the different flasks were harvested and analysed by FC for FVIII expression 
detection using the using Zenon labelling method.  
This experiment was vital for understanding the most suitable confluence for FVIII 
cell production (Fig. 15). The experiment confirmed – as expected - that expression of 
FVIII was relatively higher in cells with 50% confluence than in cells with 80% confluence, 
both in HECV and HELA (fig. 16).  
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Figure 15: Cell confluence and FVIII expression rate. FC dot plots of HELA cells stained with 
Zenon anti-FVIII antibody. (a) and (b) 50% confluent HELA FVIII and IgG. (c) and (d) 80% 
confluence. This figure shows the gating strategy shown in the ancestry plots. N=3  
 
 
  
Figure 16: Cell confluence and FVIII expression rate. FC dot plots of HECV cells stained with Zenon 
anti-FVIII antibody. (a) and (b) 50% confluent HECV FVIII and IgG. (c) and (d) 80% confluence. This 
figure shows also the gating strategy shown in the ancestry plots. N=3 
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4.9. Assessment of Lactadherin (MFGE8) blocking’s effect on expression 
of FVIII  
FVIII binds to phosphatidylserine sites on the cellular membrane. Due to this 
binding property, FVIII proteins secreted by bystander cells may attach to the cell 
membrane and confound measurements of cell-specific FVIII. 
Different blocking measures can be tested to decrease this binding and increase 
therefore the specificity of antibody staining. In this project the human recombinant 
milk protein MFGE8 (milk fat globule-EGF factor 8) or Lactadherin was used for 
this purpose. 
Lactadherin was incubated with seeded cells (U937 cells) at a concentration of 4 
nM in 24 well-culture plates overnight. The next day, cells were harvested and 
stained to detect FVIII using Zenon labelled anti-FVIII antibody labelling kit either 
intracellularly (after cell permeabilization) or extracellularly (by surface staining 
without permeabilizing the cells). The results of the of this experiment (Fig. 17) 
confirmed that Lactadherin competed with FVIII on binding on the surface and this 
was clearly shown by the noticeable reduction of FVIII percentage in the cells 
incubated with Lactadherin overnight. 
When Lactadherin was tested on intracellular staining, it did not affect the % of 
FVIII positive cells, showing that the surface unspecific binding was not a 
confounding element in the intracellular staining procedure. Therefore, we did not 
include Lactadherin treatment in the blocking steps of the intracellular FVIII 
visualization protocol.  
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Figure 17: FC for Lactadherin Competition assay: (a) Bar-chart showing FVIII% of U937 cells without 
Lactadherin vs with Lactadherin overnight (12 hrs) incubation (Mean+/- SEM of N=4, P-Value=0.0039) 
and intracellular staining . (b)(c)(d) are dotplots of FC analyses of FVIII% in U937 cells (without 
Lactadherin incubation=3.52% and with Lactadherin incubation=1.98%).  
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4.10. The proposed optimized FC staining protocol for FVIII 
characterization 
 
Table 2. The optimized protocol of FC analysis for FVIII visualization with Zenon and with 
custom labelled Abs 
 
 
Step Details Interval 
1 Harvesting of cells Wash cells once with PBS (Centrifuge). Harvest cells and count using 
Trypan blue and hemocytometer and divide cells as one million cells per 
condition. 
Centrifuge at 
300xg, for 5 min 
at RT. 
2 Live and dead 
staining 
In 1 ml of cells in PBS, add 1 µl of live/dead dye (Incubate), according 
to manufacturer protocol (LIVE/DEAD™ Viability/Vitality Kit, 
Molecular Probes) 
Incubate for 15 
min in the dark at 
RT. 
3 Staining buffer wash Wash cells in 3 ml of staining buffer: 0.1% BSA-PBS solution 
(Centrifuge). 
Centrifuge at 
300xg, for 5 min 
at RT. 
4 CD markers or 
FVIII (surface 
staining) 
Cells are re-suspended in X µl of staining buffer for surface staining, 
desired labelled surface Abs are added (total volume for surface staining 
should be 100 µl) (Incubate). 
Incubate for 30 
min in the dark at 
RT. 
5 Staining-buffer 
wash 
Wash cells in 3 ml of staining buffer: 0.1% BSA-PBS solution 
(Centrifuge). 
Centrifuge at 
300xg, for 5 min 
at RT. 
6 Cells Fixation Re-suspend cell pellet in 100 µl Fixing buffer (Incubate) according to 
manufacturer protocol (Invitrogen™ FIX & PERM™ Cell 
Permeabilization Kit). 
Incubate for 15 
min at RT. 
7 Staining-buffer 
wash 
Wash cells in 3 ml of staining buffer: 0.1% BSA-PBS solution 
(Centrifuge). 
Centrifuge at 
300xg, for 5 min 
at RT. 
8 Cells Permealization Re-suspend the cells in 100µl of perm buffer. Add 10% final 
concentration of Mouse Serum (Incubate). 
Incubate for 15 
min at RT. 
9 FVIII (Intracellular 
staining ⱡ) 
- Zenon staining: Label anti-FVIII Abs and IgG isotype control with 
Zenon labelling dye (according to manufacturer protocol of Zenon™ 
Antibody Labelling Kits Thermofisher) and add the labelled anti-FVIII 
Ab to the cells (Incubate). 
- Stably labelled anti-FVIII Abs: add to cells the labelled Abs at 
titrated concentration. (Incubate) 
Incubate for 20 
min in the dark at 
RT. 
10 Staining-buffer 
wash 
Wash cells in 3 ml of staining buffer which is 0.1% BSA-PBS solution 
(Centrifuge). 
Centrifuge at 
300xg, for 5 min 
at RT. 
11 Final Cells Fixation Re-suspend the cells in 200 µl of 2% paraformaldehyde-PBS. _ 
12 Data acquisition Acquire the results on Flow-cytometry instrument _ 
ⱡ During the incubation time, compensation beads are as well prepared for further FC acquisition, using UltraComp 
eBeads™ from Invitrogen™ with adding equivalent colors used for cellular staining. 
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The optimized protocol was then used to proof the FC analytic method of FVIII in 
different biological scenarios.  
 
4.11.  Lentiviral Vector -mediated gene transfer of FVIII in cell lines  
A 3rd generation Self Inactivating (SIN) Lentiviral vector, carrying the FVIII human 
gene under a Phosphoglycerate Kinase (PGK) promoter was used to transduce cell lines at 
different viral concentrations, measured as MOI (Multiplicity of Infection Units) to 
represent the number of viral particles added to the cells in culture. MOIs of 5 to 40 
(meaning 5 to 40 viral particles/cell) were used for the experiments.  
After a day of incubation, the viruses were removed, and the cells were grown in 
fresh culture media. Gene transfer experiments were done in the lab by Muhammed 
Elnaggar and other colleagues. 
Transduced cell lines with FVIII gene were tested for FVIII expression. As shown 
below, the genetic modification of the cells resulted in increasing FVIII expression, 
according to the MOI used, and plateauing at the highest MOI. This result demonstrated 
that FVIII transgene-derived protein can be efficiently visualized by FC. 
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4.12. Functional study of FVIII kinetics (production and trafficking 
inside cells) by studying the effect of Lactacystin proteasome inhibition  
Un-transduced and transduced cell lines were used to study FVIII protein 
accumulation effects in the cells. This is important in the field of GT, to exclude toxic 
effects in the target cells due to overexpression of the transgene. 
The first cellular response to protein accumulation is Endoplasmic Reticulum (ER)-
stress. This is associated with Ubiquitin-Proteasome System (UPS) and Unfolded Protein 
Response (UPR) pathways, leading eventually to cell autophagy if the ER stress is 
prolonged. 
Figure 18: FC FVIII analysis of U937 cells before (UT) and after transduction with LVV-FVIII at 
different MOIs: FVIII% increases with increasing transduction rate/MOI, plateauing at MOI 30. 
Mean+/- SEM of N=4.  
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To study FVIII accumulation inside the cells, we blocked the proteosomal pathway 
using Lactacystin which is a 16S proteasome inhibition protein. Lactacystin was incubated 
at 50µM concentration for 4 hours prior to FC analysis with U937 cells un-transduced or 
transduced at 5 & 30 MOIs. Proteasome inhibition leads to accumulation of misfolded 
proteins in the cells.  
After proteasome inhibition FVIII was higher both in un-transduced and transduced 
cells (fig. 19).  FVIII sharp increase after proteasomes inhibition proves that normally a 
good portion of FVIII is routed to proteasome for degradation. This happens both in un-
transduced and transduced cells and in different cell lines.  
 
 
 
Figure 19: Functional studies of FVIII. Bar graph of FC data showing that transduced U937 cells 
had higher FVIII than un-transduced cells (effect of gene transduction using PGK-FVIII-LVV 
(Mean+/- SEM).  Adding Lactacystin (LC) to cells shows the accumulation of misfolded proteins 
inside the cells (effect of LC on FVIII level).   
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The rates of FVIII in cells is directly proportional to the rate of transduction by 
FVIII-LV vector (until MOI 30, as shown in Figure 18).  
Of note, even un-transduced cells (U937 and HECV) are active in the degradation 
of existing FVIII misfolded proteins, so this suggests that careful dose-limiting analyses 
have to be calculated before administering FVIII GT products in order to avoid UPR 
pathway engulfment and consequent cell apoptosis. 
This set of experiments shows the efficiency of the optimized protocol to capture 
fine functional differences otherwise impossible to highlight with conventional FVIII 
staining techniques.   
 
4.13. FC analysis validation: Double staining of FVIII with two 
antibodies against two different domains 
To validate the optimised FC staining method and to confirm that staining positivity is truly 
of FVIII protein being detected, a double staining of cells was performed with 2 Abs 
targeting 2 different FVIII domains: light chain and A2 domains. Abs were labelled with 
different colours using Zenon (fig. 20).  
 This result confirmed the specificity of FVIII FC Ab staining by showing the co-
expression of FVIII staining of the 2 different domains.  
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This is demonstrated by the overlay plot (C) that shows FITC-labelled FVIII A2-domain 
co-expressed in the upper right quadrant with APC-labelled FVIII Light Chain-domain.  
 
* Note: Experimental results listed above were achieved in collaboration with Dr. 
Muhammad Elnaggar and other colleagues in the lab. 
  
A B C 
Figure 20: IgG1 anti A2 domain, and -anti LC domain antibodies with IgG1 isotype, were used for a comparison 
of single and double staining on U937 transduced at 30 MOI with PGK-FVIII-LVV.(A) (B) and (C) FC dot plots 
showing the double FVIII staining with respect to the isotype control. n=1 in duplicate, means and SEM shown in 
graph D. 
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CHAPTER 5: DISCUSSION  
In the field of GT, FC shows its clinical relevance when applied to the determination 
of gene transfer level on target cells. The outcome of this project suggests that FC technique 
can be adopted for assessment of GT efficiency, as it achieved a reliable measurement of 
intracellular and extracellular levels of FVIII protein in different subsets of cells. Such 
measurement of FVIII protein is not possible by currently used methods. The use of a FC 
protocol for FVIII characterization is novel and useful after the development of GT 
approaches for HA. Indeed, currently, no commercial pre-labelled anti-FVIII monoclonal 
antibody is available to perform FC analysis of cells. 
FVIII detection in current clinical diagnostics is performed mainly through plasma 
level measurements which does not enable FVIII functional studies. The recent 
development of GT approaches requires a more sophisticated analysis platform, to address 
specific issues of GT efficiency, toxicity and transgene permanence directly on target cells. 
An FC analysis able to quantify and functionally measure the transgene in target cells 
would be a useful reliable and novel tool for GT approaches on HA. Although FC is 
strongly emerging in the field of clinical research, a validated FC protocol for FVIII protein 
analysis is still missing and this increases the necessity to this project. To this aim, we 
sought to optimize in this study a protocol for FC FVIII visualization.  
We realized, after the first FC experiments on PBMCs stained with anti-FVIII 
antibodies labelled with Dylight 650 NHS ester dye, that high non-specificity patterns in 
FVIII antibodies and IgG control had to be systematically reduced, to avoid unrealistic high 
positivity results of FVIII in cells. We confirmed by a competition assay with recombinant 
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FVIII proteins that FVIII itself was un-specifically binding to membrane surfaces, and 
aggregating labelled antibodies falsely enhancing the positive threshold. 
Stickiness of FVIII protein was supposed by the natural behavior of FVIII protein, 
as pro-coagulant factor, and described by previous scientists who successfully addressed 
that FVIII has a PS of membrane binding capacity similarly to Annexin 5 (Engelke H et 
al., 2011) and Lactadherin (Dasgupta, Guchhait, & Thiagarajan, 2006). To address this, 
different blocking approaches were tested.  
PBMCs especially phagocytes like monocytes have Fc binding receptors (Swanson 
JA et al., 2004). These receptors were hypothesized to be interfering with the un-specificity 
observed as these receptors bind antibodies. To address this, Fc block and mouse serum 
block were assessed for their blocking efficacy. We observed that 10% mouse serum 
blocking gives cleaner staining of PBMCs by blocking un-specific binding sites on cells. 
Monocytes in PBMCs benefitted from mouse serum and concentrated Fc receptor block; 
however, the best specificity result was achieved by using IgG1 isotype control instead of 
IgG2a. Non-specificity in flow cytometry staining is a common issue and was under 
investigation in order to be tackled. Similarly, to what we concluded, Anderson et al. 
postulated in a technical research work in which they used PBMCs that erroneous results 
in immunostaining can be eliminated by proper isotype control and sufficient blocking at 
high concentrations (Andersen, Al-Karradi, Kragstrup, & Hokland, 2016). In our project, 
we observed that specifically mouse serum in 10% (v/v) concentration blocking is crucial 
to eliminate non-specificity due to non-specific binding sites on cells. 
Non-specificity of staining was further improved after shifting to Zenon technology 
for antibody labelling.  Antibody labelling with NHS dyes led to high leakage of color and 
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high fluorescence. Zenon unlike custom labelling, proved itself in all experiments 
performed to be a more specific labelling method. This is labelling method binds 
commercially fluorescent-labelled Fab-fragments to Fc of target antibodies; the staining 
happens outside the cell, and unbound Fab labeled fragments are quenched and washed 
away, therefore improving the specificity. As observed in PBMCs’ FC analysis, this 
immune-labelling method, provided enhanced reproducible labelling specificity and 
reduced labeling leakiness issues we faced in the early FC experiments.  
The body’s sites of FVIII production are still unclear. Apparently, there are many 
cell types other than hepatic sinusoidal cells and PBMCs, that can produce FVIII, as several 
cells are rich of FVIII RNA as proven previously in the literature (Su AI, Wiltshire T, 
Batalov S, et al., 2004). In this project, HECV, HELA and U937 cells were tested by 
quantitative PCR and confirmed their positivity for FVIII. With an aim to show the 
applicability of FC analysis on different cell types, these cells were utilized in FC analyses 
and confirmed their positivity also for FVIII protein by FC analysis. 
Cell confluence can impact cell expression pattern. Previous data showed that 
contact inhibition reduces secretion of proteins as confluent cells become stressed and 
subsequently enter quiescence which is a state of cell inactivity/dormancy as was described 
by Hayes et al. that cell confluency’s effect on cells in terms of inducing quiescence and 
affecting cell’s functions (Hayes et al. 2005). This shows the high impact of cell confluence 
on cell activities especially protein production. As noticed in HECV and HELA cells, it is 
also true for FVIII, that showed an enhanced expression when cells were less confluent as 
compared to highly confluent cells, giving insight that FVIII production is best visualized 
at FC at low cell concentration.  
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FVIII adhesiveness to the plasma membrane was studied using FC analysis. FVIII 
adhesiveness to PS parts of the membrane of cells was shown through a competition assay 
between FVIII and Lactadherin. Lactadherin adherence to membranes was previously 
described by Shi et al. and a similar property was also observed in Annexin 5 (Shi et al., 
2004; Dasgupta, Guchhait, & Thiagarajan, 2006). Lactadherin block only affected FVIII 
extracellular adherence but did not reduce/affect intracellular FVIII levels; thus, 
Lactadherin block was not implemented in the FC analysis protocol as the main interest of 
this study was to visualize intracellular FVIII. 
FVIII FC protocol after optimization, served as a tool to perform FVIII functional 
studies; and to investigate FVIII expression in different scenarios. Such FC FVIII studies 
were the first to be performed in literature. 
The first scenario was the LVV gene-transduction mediated FVIII production. We 
observed that FVIII expression gradually increased after increasing the transduction rate 
(MOI) showing that gene transfer is effective in making cells produce FVIII in high 
amounts. It can be suggested that, with very high viral load, cells can be stressed and FVIII 
expression can be reduced. This was inferred by the evidence of FVIII plateauing at 40 
MOI of transduction.  
Protein being routed to proteasomal degradation pathway occurs in normal cells 
and most importantly in transduced cells as a result of protein overload. Cellular stress due 
to FVIII protein accumulation inside cells, can lead to FVIII degradation and if overloading 
the UPR machinery, to cell apoptosis. This study showed that FC analysis visualizes FVIII 
expression in transduced and un-transduced cells, and FVIII misfolded protein 
accumulation by proteasome inhibition through Lactacystin.  
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FVIII intracellular accumulation due to AAV mediated gene transduction was 
studied previously by Sabatino et al. similarly showing that FVIII accumulation inside the 
cells can activate UPR pathway as Sabatino and his colleagues were able to show by 
different experiments mainly through quantitative PCR showing that cells after gene-
transfer induced protein production can lead to accumulation and activation of Unfolded 
protein response (Sabatino et al., 2017). 
To confidently show that FVIII positivity in the staining was truly to FVIII and not 
staining artefacts, double staining FC analysis was done to target 2 different FVIII domains 
with 2 different fluorescence. The data confirmed that staining is specific towards FVIII 
and not staining artefacts, by showing co-expression of the 2 domains.  
It is important to note that the staining protocol was confirmed by multiple lab 
operators performing the steps and achieving reproducible results and multiple samples 
being processed showing also consistent results.  
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CHAPTER 6: CONCLUSION & FUTURE DIRECTIONS 
  We demonstrated that, after deep and thorough optimization, a robust FC analysis 
on large proteins as FVIII is possible and is of great importance. This analysis enables 
measurements that were impossible so far, like functional quantification of intracellular 
FVIII, potentially applicable as an advanced diagnostic tool both in HA patients and in HA 
patients treated with GT.  
We succeeded in optimizing this protocol in PBMCs and in different cell lines, 
transduced and un-transduced. This suggests that FC visualization of FVIII can be broadly 
applied to any FVIII producing cells.  
Future directions would be to implement this FC protocol in real clinical practice 
i.e. for diagnosis of HA patients, and for follow up of HA patients receiving GT, by 
performing FC analysis to assess GT efficiency and eventual toxicity on target cells. 
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